吸收不良综合征市场规模、份额、增长分析、按致病原因、按诊断、按给药途径、按治疗、按最终用户、按地区 - 2025 年至 2032 年行业预测

吸收不良症候群市场规模预计在 2023 年达到 31 亿美元，到 2032 年将达到 56.5 亿美元，预计在预测期内（2025-2032 年）的复合年增长率为 6.9%。

由于生活方式、饮食习惯的改变和人口老化等因素导致吸收不良症候群的盛行率不断上升，全球吸收不良症候群市场正在成长。此外，乳糜泻和克隆氏症疾病的治疗也导致对有效诊断和治疗方案的需求不断增长。诊断技术的显着进步，包括增强成像技术、生物标记识别和基因检测，大大提高了诊断吸收不良综合征的准确性和速度，使医疗保健提供者能够及时采取干预措施。此外，患者和医疗保健专业人员的意识提高有助于早期发现和管理病情。教育宣传活动和资讯传播工作使个人能够及时寻求医疗救助，最终在治疗吸收不良症候群方面取得更好的健康结果。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

吸收不良症候群市场规模（按病因和复合年增长率） (2025-2032)

• 市场概览
• 囊肿纤维化
• 寄生虫病
• 肠道疾病
  • 乳糜泻
  • 其他的
• 乳糖不耐症
• 惠普尔氏症
• 热带口炎性腹泻
• 其他的

吸收不良症候群市场规模（按诊断和复合年增长率）（2025-2032）

• 市场概览
• 影像学检查
  • 电脑断层扫描
  • 经内视镜逆行性胆胰管摄影术（ERCP）
  • 磁振造影胰造影（MRCP）
  • 腹部X光检查
• 血液检查
• 其他的
  • 脂肪吸收不良试验
  • 碳水化合物吸收测试
  • 席林检验
  • D-木糖测试
  • 胆盐吸收试验
  • CD-木糖呼吸检测

吸收不良症候群市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 监护人

吸收不良症候群市场规模（依治疗类型及复合年增长率）（2025-2032）

• 市场概览
• 无麸质饮食
• 抗发炎药物
• 抗生素
• 营养补充品
• 蛋白酶和脂肪酶补充剂
• 止泻药
• 其他的

吸收不良症候群市场规模（依最终用户和复合年增长率） （2025-2032）

• 市场概览
• 医院
• 学术研究所
• 製药公司
• 营养诊所
• 其他的

吸收不良症候群市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • 艾伯维公司（美国）
    • 阿斯特捷利康公司（英国）
    • 拜耳公司（德国）
    • 礼来公司（美国）
    • 葛兰素史克公司（英国）
    • 辉瑞公司（美国）
    • 赛诺菲（法国）
    • 诺华公司（瑞士）
    • 默克公司（美国）
    • 帝斯曼（荷兰）
    • 雀巢健康科学（瑞士）
    • 武田药品工业株式会社（日本）
    • Perrigo Company plc（爱尔兰）
    • Lupin Pharmaceuticals, Inc.（印度）
    • Mallinckrodt製药公司（英国）
    • 克莱尔实验室（美国）
    • 美国国家酵素公司
    • Organon & Co.（美国）
    • Ferring BV（瑞士）
    • 百特国际公司（美国）

结论和建议

Malabsorption Syndrome Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.31 billion in 2024 to USD 5.65 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Malabsorption Syndrome market is witnessing growth driven by rising prevalence attributed to factors such as lifestyle changes, dietary habits, and an aging population. Conditions like celiac disease and Crohn's disease are also contributing to increased demand for effective diagnostic and treatment solutions. Notable advancements in diagnostic technologies, including enhanced imaging techniques, biomarker identification, and genetic testing, have significantly improved the accuracy and speed of diagnosing Malabsorption Syndrome, allowing healthcare providers to initiate timely interventions. Moreover, heightened awareness among patients and healthcare professionals has fostered early detection and management of symptoms. Educational campaigns and information dissemination efforts are empowering individuals to seek medical attention promptly, ultimately leading to better health outcomes in managing Malabsorption Syndrome.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segments Analysis

Global Malabsorption Syndrome Market is segmented by Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User and region. Based on Causative Diseases, the market is segmented into Cystic Fibrosis, Parasitic Diseases, Intestinal Disorders, Lactose Intolerance, Whipple's Disease, Tropical Sprue and Others. Based on Diagnosis, the market is segmented into Imaging Studies, Hematologic Tests and Other Tests. Based on Route Of Administration, the market is segmented into Oral and Parental. Based on Treatment, the market is segmented into Gluten-Free Diet, Anti-Inflammatory Drugs, Antibiotics, Nutritional Supplements, Protease And Lipase Supplements, Antidiarrheal Agents and Others. Based on End-User, the market is segmented into Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Nutrition Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Malabsorption Syndrome Market

The increasing incidence of malabsorption syndromes, driven by shifting lifestyles, dietary habits, and an aging population, has significantly heightened the need for effective diagnostic and treatment solutions. As awareness among both healthcare professionals and patients rises, along with advancements in diagnostic technologies, the early identification and management of these disorders have become more feasible. This proactive approach has positively influenced market expansion, as the demand for innovative therapies and diagnostic tools continues to grow. Overall, the combination of these factors is propelling the growth of the malabsorption syndrome market, highlighting the importance of addressing these health challenges.

Restraints in the Malabsorption Syndrome Market

A significant constraint in the Malabsorption Syndrome market arises from the intricate and varied characteristics of malabsorption disorders, which complicate accurate diagnosis and effective treatment. Economic factors, reimbursement challenges, and inconsistencies in healthcare infrastructure across different regions further impede the delivery of optimal patient care. Moreover, the elevated costs associated with advanced diagnostic technologies and specialized treatments can limit accessibility for certain groups, ultimately affecting widespread adoption and management of these conditions. This multifaceted landscape presents notable hurdles for healthcare providers and patients alike, making it challenging to address the needs of those suffering from malabsorption syndromes effectively.

Market Trends of the Malabsorption Syndrome Market

The malabsorption syndrome market is witnessing a significant trend towards personalized medicine, emphasizing tailored diagnostic and therapeutic strategies aligned with individual patient profiles. This shift is bolstered by advancements in genetic testing and biomarker identification, enabling precise interventions that address the unique causes of malabsorption issues. Furthermore, the development of novel therapeutic modalities, including biologics and gene therapies, illustrates a commitment to innovative approaches in treatment. As healthcare evolves towards more customized care, stakeholders in the malabsorption syndrome market are increasingly focusing on leveraging these advancements to enhance patient outcomes and overall market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Malabsorption Syndrome Market Size by Causative Diseases & CAGR (2025-2032)

• Market Overview
• Cystic Fibrosis
• Parasitic Diseases
• Intestinal Disorders
  • Celiac Disease
  • Others
• Lactose Intolerance
• Whipple's Disease
• Tropical Sprue
• Others

Global Malabsorption Syndrome Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Imaging Studies
  • CT Scan
  • Endoscopic Retrograde Cholangiopancreatogram (ERCP)
  • Magnetic Resonance Cholangiopancreatography (MRCP)
  • Abdominal X-Ray
• Hematologic Tests
• Other Tests
  • Test Of Fat Malabsorption
  • Tests Of Carbohydrate Absorption
  • Schilling Test
  • D-Xylose Test
  • Test Of Bile Salt Absorption
  • C-D-Xylose Breath Test

Global Malabsorption Syndrome Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parental

Global Malabsorption Syndrome Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Gluten-Free Diet
• Anti-Inflammatory Drugs
• Antibiotics
• Nutritional Supplements
• Protease And Lipase Supplements
• Antidiarrheal Agents
• Others

Global Malabsorption Syndrome Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Academic And Research Institutes
• Pharmaceutical Companies
• Nutrition Clinics
• Others

Global Malabsorption Syndrome Market Size & CAGR (2025-2032)

• North America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • US
  • Canada
• Europe (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Klaire Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• National Enzyme Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring B.V. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations